Table 3.
Univariate analysis of 30-day outcome of ICH among patients with hematological malignancies.
| Alive (n = 26) | Dead (n = 46) | Univariate analysis, P value | Multivariate analysis, P value (odds ratio; 95% CI) | |
|---|---|---|---|---|
| Gender: | 0.604 | |||
| Male | 16 | 32 | ||
| Female | 10 | 14 | ||
| Age | >0.999 | |||
| ≥60 years | 12 | 20 | ||
| <60 years | 14 | 26 | ||
| Hematological malignancies | 0.679 | |||
| AML | 14 | 29 | ||
| APL | 5 | 4 | ||
| ALL | 2 | 3 | ||
| Lymphoma | 3 | 4 | ||
| Myeloma | 2 | 6 | ||
| Remission status | 0.448 | |||
| Yes | 4 | 4 | ||
| No | 22 | 42 | ||
| Post HSCT | 0.473 | |||
| Yes | 2 | 7 | ||
| No | 24 | 39 | ||
| Underlying hypertension | >0.999 | |||
| Yes | 7 | 12 | ||
| No | 19 | 34 | ||
| Sepsis | 0.050 | |||
| Yes | 8 | 26 | ||
| No | 18 | 20 | ||
| CNS involvement | >0.999 | |||
| Yes | 2 | 4 | ||
| No | 24 | 42 | ||
| Subarachnoid hemorrhage | 0.007 | 0.021 (10.9; 1.3 to 88.9) | ||
| Yes | 1 | 14 | ||
| No | 25 | 32 | ||
| Multifocal hemorrhage | 0.006 | 0.026 (4.7; 1.6 to 14.0) | ||
| Yes | 6 | 27 | ||
| No | 20 | 19 | ||
| Surgical intervention | 0.085 | |||
| Yes | 7 | 4 | ||
| No | 19 | 41 | ||
| Leukocyte count | >0.999 | |||
| ≥100,000 cells/μl | 4 | 8 | ||
| <100,000 cells/μl | 22 | 38 | ||
| Platelet count | 0.802 | |||
| ≥20,000 cells/μl | 16 | 30 | ||
| <20,000 cells/μl | 10 | 16 | ||
| Prolongation of prothrombin time | 0.013 | 0.008 (10.9; 1.3 to 85.5) | ||
| INR ≥1.5 | 1 | 14 | ||
| INR <1.5 | 24 | 32 |
ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; APL = acute promyelocytic leukemia; CNS = central nervous system; HSCT = hematopoietic stem cell transplantation; ICH = intracranial hemorrhage; INR = international normalized ratio.